**Other Names**
FEIBA NF, Factor Eight Inhibitor Bypassing Activity, Anti-Inhibitor Coagulant Complex

**Pre-Transfusion Sample**
- ☒ Not Required
- ☐ Blood Group
- ☐ Group & Screen
- ☐ Crossmatch

**Approval Requirements**
Product must be ordered by clinical hematologist or Hemophilia Clinic Nurse Practitioner with required privileges.

**Product Description**
Freeze-dried, sterile human plasma fraction with Factor VIII inhibitor bypassing activity. Contains factors II, IX and X, mainly non-activated, and factor VII, mainly in the activated form. Vapor treated and nanofiltered to reduce the risk of viral transmission.

Available in 1000 U and 2500 U vial sizes. Units of FEIBA vary with each lot number. The nearest combination of whole vials must be used to deliver the prescribed dose.

Supplied as a lyophilized product with sterile water diluent. Reconstituted and filtered into a syringe in Transfusion Medicine.

**Clinical Indications**
- Control of spontaneous bleeding episodes in patients with hemophilia A or B who have inhibitors to factor VIII or factor IX.
- Surgical interventions in patients with hemophilia A or B who have inhibitors to factor VIII or factor IX.
- Life threatening hemorrhage in non-hemophilia patients who have inhibitors to factors VIII, XI or XII.

**Contraindications**
Should not be used for patients with:
- Normal coagulation.
- Significant signs of disseminated intravascular coagulation (DIC) or fibrinolysis.
- Bleeding episodes resulting from coagulation factor deficiencies.
- Hypersensitivity to the product.

**Risks**
Allergic and anaphylactic reactions and hypertension.

As FEIBA is a plasma product there is a risk for transmission of infection.

High dose treatment:
Treatment with high doses of FEIBA may increase the risk of thrombotic and thromboembolic events including DIC, myocardial infarction, venous thrombosis, stroke and pulmonary embolism.

High risk patients:
Patients with DIC, atherosclerotic disease, crush injury, septicemia, or concomitant treatment with recombinant factor VIIa have increased risk of developing thrombotic events.

FEIBA should be administered to pregnant and lactating women only if clearly indicated.

Vaccination against hepatitis A and hepatitis B should be considered for patients who regularly receive FEIBA.
**Dosage**

Many patients carry a Factor First card with pertinent information about their prescribed therapy.
Consult with the Hematologist-on-call for dosing and prescribing guidelines
The dosage must be individualized according to the needs of the patient.

**Administration**

**Visually inspect** for particulate matter and discoloration prior to administration.
**Refer to:**
- Administering Medications Using IV Push Method
- Product monograph

**Administer:**
- By slow intravenous injection or intravenous infusion
- At room temperature
- Through a separate injection site
- Intravenous injection at a rate not exceeding 2 U/kg/min or 120 U/kg/hr
- IV infusion rate is usually over 40 to 45 minutes however must not exceed a rate of 2 U/kg/min

**Compatible Solution**

The manufacturer does not recommend any compatible fluids.
**Flush** the line before and after administration with 0.9% Normal Saline only.
**Do not** mix FIEBA with other medicinal products or intravenous admixtures.

**Infusion Rates**

**Maximum** injection or infusion rate must not exceed 2 U/kg/min.

**Monitoring**

**Remain** with, or be in a position to **closely observe**, the patient for the first 15 minutes following the start of each injection/infusion (when product actually reaches the patient) and observe for signs and symptoms of a transfusion reaction.

**Record vital signs:**
- After 15 minutes
- Within 15 minutes of completion of the injection/infusion

⚠ Increase observation for high risk patients.

In the event of a suspected transfusion reaction, **refer** to Transfusion Reaction Procedure & Quick Reference guide and complete Transfusion Reaction Report Form.
For outpatients, **REVIEW** post transfusion care and **GIVE** the “Heading Home After a Transfusion” form to the patient/family.

**Storage Conditions**

Stored at room temperature not to exceed 25 °C.

**For reconstituted product:**
- Store at room temperature
- Administer within 3 hours of reconstitution.
- Return product and Transfusion Record to Transfusion Medicine within 20 minutes from time of issue if there are any delays in administration.
- Do not refrigerate or store on nursing unit.
### References